Quantcast
Last updated on April 21, 2014 at 4:56 EDT

Latest Acetylcholine Stories

2011-09-16 11:35:55

Scientists have identified a surprising new role for a new type of T cell in the immune system: some of them can be activated by nerves to make a neurotransmitter (acetylcholine) that blocks inflammation. The discovery of these T cells is novel and suggests that it may be possible to treat inflammation and autoimmune diseases by targeting the nerves and the T cells. The study was published this week in Science. "The discovery that 2 percent of T cells can make acetylcholine under the...

2011-09-16 06:00:00

CHICAGO, Sept. 16, 2011 /PRNewswire/ -- Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011, in Chicago. The abstracts provide additional data that demonstrate the safety and routes of administration of CEM-101, a new generation macrolide. CEM-101 is a fluoroketolide...

2011-09-02 09:00:00

Company maintains the reason is over 30 years of R&D that resulted in the âœonly brain pill that really works.â Laguna Beach, California (PRWEB) September 02, 2011 Procera AVH®, a unique âœcognitive and mood enhancer,â is the first clinically validated natural supplement shown to significantly improve mind, mood and memory, reversing up to 15 years of mental decline. Procera AVH® was developed and is...

2011-08-25 12:04:53

Scientists at Yale University have developed the first practical method to create a compound called huperzine A in the lab. The compound, which occurs naturally in a species of moss found in China, is an enzyme inhibitor that has been used to treat Alzheimer's disease in China since the late 1990s and is sold in the U.S. as a dietary supplement to help maintain memory. Scientists believe it could also potentially combat the effects of chemical warfare agents. Until now, researchers have...

76d0227ac22b20cead582d38c76b219f
2011-08-19 10:00:08

Researchers at the Faculty of Pharmaceutical Sciences at the University of Copenhagen have collaborated with the company NeuroSearch to generate new knowledge about an important part of the brain's complex communication system. The discovery could form the basis for future development of better medicines for patients with psychiatric disorders. The results were recently published Journal of Neuroscience. New knowledge challenges established scientific ideas about the function of the...

2011-08-16 08:00:00

ANNAPOLIS, Md., Aug. 16, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company has been awarded a $5.7 million contract under a Department of Defense (DoD) Broad Agency Announcement for studies directed at the development of an advanced expression system for the bioproduction of its nerve agent medical countermeasure program. rBChE is a recombinant form of a...

2011-08-15 12:07:33

New research led by scientists from Imperial College London explains why around half of people with asthma experience a 'late phase' of symptoms several hours after exposure to allergens. The findings, published in the journal Thorax, could lead to better treatments for the disease. An estimated 300 million people suffer from asthma, and the prevalence is rising. Symptoms are commonly triggered by allergens in the environment, such as pollen and dust mites. These stimuli can cause the airways...

2011-06-22 10:19:00

QUEBEC CITY, June 22, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that CEO Martin Driscoll will be presenting at the 2011 BIO Business Forum during the annual BIO International Convention. Mr. Driscoll's presentation will be given in the Georgetown Room of the Walter E. Washington Convention Center in Washington, DC on...

2011-05-16 14:21:04

Researchers in Baltimore have identified new compounds whichrelax airway muscles and may provide relief from shortness of breath for patients with COPD and asthma. The bitter-tasting compounds are at least as, if not more, effective than currently available agents used to manage these diseases, and may present new options for treatment. The study will be presented at the ATS 2011 International Conference in Denver. "We have identified compounds that are more potent than our previously...

2011-05-08 23:01:00

MADISON, Wis., May 9, 2011 /PRNewswire/ -- Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System (CNS) disorders, announces that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug designation for MCD-386CR, its lead drug candidate, for the treatment of Progressive Supranuclear Palsy (PSP). Orphan status entitles Mithridion to seven years of market exclusivity upon approval of MCD-386 for treating PSP, and...